SecBot SecBot

TTRX drug pipeline

Turn Therapeutics Inc. · 1 rated drug
$8.55
−8.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 2
Time to market~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.

GX-03 Updated Jul 7

What to watch

GX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).

Bull case
  • Interim Phase 2 data (N=50) showed compelling efficacy, 92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at Week 4, with 79.43% mean EASI reduction vs 50.55% vehicle (source: SEC 8-K filed June 3, 2026, via businesswire.com).
  • Zero treatment-related serious adverse events and no discontinuations; safety profile appears clean (source: SEC 8-K filed July 7, 2026, via sec.gov).
  • First-in-class topical IL-36/IL-31 inhibitor, novel mechanism that avoids systemic immunosuppression of JAK inhibitors or steroids; could differentiate in a crowded AD market (source: turntherapeutics.com).
Bear case
  • Phase 2 Stage 1 data came from small subgroups (n=13-14 GX-03, n=12-18 vehicle), numbers may not replicate in the larger Stage 2 population of ~120-135 patients (source: SEC 8-K analysis report, July 7, 2026).
  • High vehicle/placebo response (50.55% EASI reduction) could dilute the treatment effect in later-stage, larger trials.
  • Crowded atopic dermatitis market includes approved topicals (Opzelura/ruxolitinib, Eucrisa/crisaborole, Protopic/tacrolimus, Zoryve/roflumilast) and injectable biologics (Dupixent, Adbry). No head-to-head data vs these standards.